Turning Point Therapeutics Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: July 14th, 2021
Here are a few of the most interesting Turning Point Therapeutics statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Turning Point Therapeutics Facts
- Website: Official Website
- Year Founded: 2013
- Headquarters: San Diego, CA
- Founder(s): J Jean Cui and Y Peter Li
What is Turning Point Therapeutics?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. (source)
Turning Point Therapeutics Employee Count
Number of Turning Point Therapeutics employees:
Last updated 3/18/19
Please note that some of these numbers are easier to find than others. A few of these Turning Point Therapeutics stats come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.